BNP Paribas upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a strong sell rating to a hold rating in a report issued on Tuesday morning,Zacks.com reports. GMAB has been the subject of a ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) climbed 7% following the announcement of its fourth-quarter earnings, which revealed a net profit significantly surpassing consensus estimates. The ...

Genmab AS (GMAB) reports a 31% revenue increase and outlines strategic plans for 2025 amidst competitive market challenges.

Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by ...

Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...

Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...